Rigor Reviewed

Rigor-Reviewed Manuscript

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Name: Adcurare Rigor Record — An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Item: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Rating: 59
Author: Adcurare

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Adcurare Rigor Review — 3★ (Adequate), 0 critical, 9 high issues for “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.”

Links back to this Rigor Record.

Adcurare Editorial

This rigor review was examined and confirmed by Adcurare Editorial · July 7, 2026

Adcurare Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Mixed Methods

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingBiological variables not met−0.5★
ReportingStudy design partially met−0.25★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★
ReportingData & code availability partially met−0.25★
ReportingReporting transparency partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.6.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced7 types

Biological variables not reported
Statistical reporting gaps (tests, assumptions, effect sizes)
Data/code availability incomplete
Ethics/consent reporting incomplete
Key resources under-identified (antibodies, cell lines, RRIDs)
Reporting/transparency gaps
Study-design details incomplete (controls, blinding, power)

This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a well-premised mixed preclinical/phase 1 study of a liver-restricted LXR inverse agonist with adequate scientific premise, trial registration, and some detailed methods. Major weaknesses include missing randomization/blinding details for both preclinical and clinical components, incomplete biological variable reporting for animal studies, and lack of cell line authentication and reagent catalog numbers.

The three independent reviewers agreed on most dimensions but diverged slightly on biological variables (Reviewer 2 pass vs. Reviewer 3 fail) and reporting transparency (Reviewer 3 pass vs. warn). Synthesized judgments weigh all evidence. The statistics verification component found 0 recomputable tests, so no mathematical errors were identified, but statistics correctness is unverified for all tests.

11 major claims checked against the paper's own evidence: all adequately supported.

Reporting

Eight Dimensions1 pass · 6 warn · 1 fail

The paper extensively cites prior research on LXR's role in lipid metabolism (references 17-23), the rationale for LXR inverse agonists (references 34-37), and discusses the limitations of systemic LXR repression (e.g., impaired reverse cholesterol transport), which the liver-restricted design aims to mitigate. Limitations of prior work are addressed in the design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The scientific premise is well-established through cited prior work on LXR biology, the rationale for developing an LXR inverse agonist, and the limitations of prior approaches are addressed.

Evidence

direct quote[Introduction, paragraphs 2-4]

“LXR activation increases liver and plasma TG and LDL-C in animal models and humans by upregulating DNL genes... by contrast, repression of LXR activity in the liver reduces hepatic DNL and, consequently, plasma and liver TG.”

direct quote[Introduction, paragraph 4]

“Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport (RCT)...”

direct quote[Introduction, paragraph 4]

“However, to date, no LXR inverse agonist has been evaluated in humans.”

PASSReviewer 2· 95% conf

The scientific premise is well-established through extensive citation of prior work on LXR biology, dyslipidemia, and the rationale for LXR inverse agonists, with acknowledged limitations of systemic LXR repression.

Evidence

direct quote[Introduction, paragraph 4]

“Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport (RCT), the efflux of cholesterol from peripheral cells such as macrophages, which could promote atherogenesis and negatively impact cardiometabolic health.”

direct quote[Abstract]

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

direct quote[Introduction, paragraph 5]

“However, to date, no LXR inverse agonist has been evaluated in humans.”

PASSReviewer 3· 95% conf

The paper clearly establishes LXR biology as a therapeutic target for dyslipidemia, cites prior work, and addresses the risk of impairing reverse cholesterol transport.

Evidence

direct quote[Introduction, paragraphs 1-4]

“LXR activation increases liver and plasma TG and LDL-C in animal models and humans by upregulating DNL genes... Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport.”

direct quote[Introduction, paragraph 4]

“Here, we leveraged human genetic data, dysmetabolic rodent models, humanized experimental models, toxicology studies and a phase 1 clinical trial to evaluate the tolerability and efficacy of TLC-2716...”

direct quote[Discussion, paragraph 1]

“The limited systemic activity of TLC-2716 likely minimizes the risk of disrupting RCT (as demonstrated by unchanged expression of relevant genes in rodents and humans) and potential proatherogenic effects that have been linked to systemic LXR repression.”

For preclinical studies: randomization method (e.g., how animals were assigned to groups) and blinding levels (e.g., who was blinded during assessments) are not reported; these are applicable. Replicate distinction (biological vs technical replicates) is not explicitly stated. Power analysis is not reported. Inclusion/exclusion criteria are reported for some models (e.g., ZDF rats), but pre-specified criteria are not always clear. Outlier handling is not addressed. Controls (vehicle) are described. Independent replication is partially addressed with multiple models and a clinical trial. For the phase 1 trial: randomization is stated (8 per dose, 2 placebo) but method not detailed; blinding is not explicitly described; power analysis is stated as not used. This yields fewer than 60% of applicable sub-criteria adequate, resulting in a 'warn'.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingNOT REPORTED

randomization unitADEQUATE

inclusion exclusionINADEQUATE

randomization methodINADEQUATE

replicate distinctionNOT REPORTED

independent replicationADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 90% conf

The study combines preclinical and human components. Preclinical design lacks randomization/blinding details; the phase 1 trial is well-designed with randomization and placebo control but lacks a formal power analysis and detailed blinding description.

Evidence

absence[Methods, animal studies]

Blinding is not mentioned for preclinical studies.

direct quote[Methods, Statistical analyses]

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

direct quote[Methods, Study design]

“For each cohort, eight participants were randomized to receive TLC-2716, and two participants were randomized to receive placebo”

absence[Methods, Study design]

Blinding for the clinical trial is not described.

direct quote[Methods, Inclusion and exclusion criteria]

“In brief, eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2, inclusive at screening.”

WARNReviewer 2· 85% conf

The preclinical study design is generally adequate with controls and replicates, but the phase 1 trial lacks a formal power analysis and randomization/blinding details are not fully described for the clinical component.

Evidence

direct quote[Methods, Phase 1 clinical trial, Study design]

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

direct quote[Methods, Phase 1 clinical trial, Statistical analyses]

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

absence[Methods, Phase 1 clinical trial]

Blinding is not mentioned anywhere in the clinical trial methods.

WARNReviewer 3· 80% conf

The phase 1 clinical trial is randomized and placebo-controlled, but lacks explicit randomization method, blinding, and power analysis; preclinical studies lack randomization and blinding details.

Evidence

direct quote[Methods, Phase 1 clinical trial]

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

direct quote[Methods, Statistical analyses]

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

direct quote[Methods, Inclusion and exclusion criteria]

“In brief, eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2, inclusive at screening.”

The human phase 1 trial reports age, sex, and BMI. However, preclinical efficacy studies use male animals without justification (e.g., 'HFD-DIO mice (n = 6 per group)' without stating sex, age, or weight). Housing conditions are only described for the toxicology study. Species/strain are partially reported (e.g., 'CD-1 mice', 'cynomolgus monkeys') but not with full details. The lack of sex reporting in most animal experiments is a significant gap.

Sub-criteria

demographicsADEQUATE

sex reportedINADEQUATE

sex justifiedNOT REPORTED

age weight healthNOT REPORTED

housing conditionsINADEQUATE

species strain sourceINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Sex is reported for some preclinical studies (e.g., NHP toxicology uses both sexes) and clinical trial (self-reported), but justification for single-sex studies is missing. Age, weight, species, strain, and source are well-reported for animal models. Demographics for the clinical trial are partially reported (age, sex, BMI) but race/ethnicity is omitted.

Evidence

direct quote[Results, paragraph 8 (preclinical), Extended Data Fig. 7]

“Dose-dependent reductions in plasma TG and TC were observed in TLC-2716-treated monkeys (Extended Data Fig. 7)... in CD-1 mice treated with... both sexes”

absence[Table 1, Baseline characteristics]

Demographics for the clinical trial lack race/ethnicity.

direct quote[Methods, animal studies]

“C57BL/6J mice, aged 8–10 weeks, were fed a high-fat diet (HFD, 60% kcal fat) for 12 weeks to induce obesity.”

PASSReviewer 2· 90% conf

Biological variables are well-reported for both preclinical and clinical components, including sex, age, weight, species/strain, and human demographics.

Evidence

direct quote[Methods, Toxicity study, NHPs]

“A 4-week GLP toxicology study was conducted in cynomolgus monkeys... to evaluate the safety profile of TLC-2716 administered orally once daily at 1, 5 and 15 mg per kg (body weight) per day.”

direct quote[Results, TLC-2716 was well tolerated...]

“At baseline, mean plasma TG was 102 ± 39 mg dl⁻¹ and LDL-C was 111 ± 30 mg dl⁻¹; TG ≥ 100 mg dl⁻¹, RC ≥ 20 mg dl⁻¹ and LDL-C ≥ 100 mg dl⁻¹ were observed in 23, 20 and 30 individuals, respectively (Table 1).”

direct quote[Methods, Toxicity study, CD-1 mice]

“Animal housing facilities were maintained at 20–26 °C with 30–70% humidity. Mice were kept on a 12-h light/12-h dark cycle with ad libitum access to food and water.”

FAILReviewer 3· 85% conf

Sex, age, weight, and housing conditions are not reported for most animal studies; the human trial reports demographics but animal data are incomplete.

Evidence

direct quote[Results, paragraph 2 and Figure 2 legends]

“c – f , Liver target engagement assessed by the expression of LXR target genes ( c ), liver TG content ( d ), plasma TG AUC ( e ) and plasma TC AUC ( f ) in HFD-DIO mice ( n = 6 per group), HFD-fed SD rats ( n = 6 per group) and HFD-fed ZDF rats ( n = 6 for vehicle and 5 for the treatment group) treated with TLC-2716; Ctrl, control.”

direct quote[Results, paragraph 6 and Table 1]

“At baseline, mean plasma TG was 102 ± 39 mg dl−1 and LDL-C was 111 ± 30 mg dl−1; TG ≥ 100 mg dl−1, RC ≥ 20 mg dl−1 and LDL-C ≥ 100 mg dl−1 were observed in 23, 20 and 30 individuals, respectively (Table ).”

direct quote[Methods, Toxicity study]

“Animal housing facilities were maintained at 20–26 °C with 30–70% humidity. Mice were kept on a 12-h light/12-h dark cycle with ad libitum access to food and water.”

For the clinical trial: IRB approval is named (Northern B Health and Disability Ethics Committee, protocol 2022 FULL 12858), informed consent is described (written informed consent obtained), and regulatory compliance (relevant local policies) is stated. However, for animal studies, the methods state 'All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee' but the specific institution is not named, making it reported_but_inadequate. No specific animal regulatory compliance (e.g., Guide for the Care and Use of Laboratory Animals) is named, only 'international guidelines'.

Sub-criteria

iacuc statementINADEQUATE

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 95% conf

The phase 1 clinical trial has ethics approval and informed consent, but the NAMED approving body for animal studies is not provided (only a generic statement).

Evidence

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“Written informed consent was obtained before enrollment.”

direct quote[Methods, Toxicity study, NHPs]

“All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee and were conducted in accordance with international guidelines for the care and use of laboratory animals.”

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported for both the animal studies and the human clinical trial, with named ethics committees and informed consent.

Evidence

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“Written informed consent was obtained before enrollment.”

direct quote[Methods, Toxicity study, NHPs]

WARNReviewer 3· 95% conf

Ethics approval for the clinical trial is stated with a named committee and protocol number, and informed consent is documented; animal studies have IACUC approval. However, the human regulatory compliance statement is vague.

Evidence

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

direct quote[Methods, Phase 1 clinical trial, Study oversight]

“Written informed consent was obtained before enrollment.”

direct quote[Methods, Toxicity study]

For the clinical trial: investigational product TLC-2716 is named and its patent is referenced, but formulation/strength/dose are described in the text (e.g., 0.5-12 mg). Assay kits (e.g., NMR LipoProfile, Labcorp) are named but no catalog numbers. For preclinical: organisms are identified (C57BL/6J, SD rat, ZDF rat) with sources (e.g., Charles River), but no RRIDs. Antibodies are not used. Cell lines: iPS cells are used but source, authentication (STR profiling), and mycoplasma testing are not reported. Key reagents (e.g., sodium oleate, BODIPY 493/503) are named with vendors but no catalog numbers. Software: some tools are identified with versions (e.g., STAR version 2.73a, Limma version 3.60.0, TwoSampleMR v0.6.2), but not all (e.g., 'Hybrid Cell Count application' no version). This results in <60% adequate.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedINADEQUATE

antibodies identifiedN/A

cell line authenticationNOT REPORTED

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

The investigational product TLC-2716 is identified, but key reagents (antibodies, cell lines, organisms, software) are not consistently identified with catalog numbers, RRIDs, or versions. The clinical trial product is described, but assay kits and some software lack full identification.

Evidence

absence[Methods, HLO models of steatohepatitis]

Cell lines (iPS) are used but no authentication or mycoplasma testing reported.

direct quote[Methods, HLO models, Statistical analyses]

“Lipid droplet volume was quantified using the Hybrid Cell Count application (Keyence)...”

direct quote[Methods, HLO models]

“sHLOs were rinsed three times with prewarmed PBS and stained with 2 μM BODIPY 493/503 (Thermo Fisher Scientific)”

WARNReviewer 2· 80% conf

Key resources are partially identified; the investigational drug TLC-2716 is named but lacks a catalog number or source, and software versions are reported, but antibodies and cell lines are not fully identified.

Evidence

direct quote[Results, LXR inverse agonists lower TG...]

“TLC-2716 (ref. ¹⁸) and its analog TLC-6665 (ref. ¹⁹) are two LXR inverse agonists. Information on these compounds is available in patent US11970484B2 (ref. ²⁰; Supplementary Fig. 1).”

direct quote[Methods, RNA-sequencing analysis]

“Alignment was performed against the human genome (GRCh38, v113) following the STAR (version 2.73a) manual guidelines.”

paraphrase[Methods, HLO models of steatohepatitis]

“HLOs were generated from human iPS cells, but the source or catalog number of the iPS cells is not provided.”

FAILReviewer 3· 85% conf

The investigational drug TLC-2716 is not fully identified (manufacturer, lot number not provided); cell lines (iPS) are not authenticated; mycoplasma testing is not reported; animal strains are partially identified; software tools are well identified.

Evidence

direct quote[Results, paragraph 1 and Methods]

“TLC-2716 (ref. ) and its analog TLC-6665 (ref. ) are two LXR inverse agonists. Information on these compounds is available in patent US11970484B2 (ref. ; Supplementary Fig. ).”

paraphrase[Methods, HLO models of steatohepatitis]

“The methods describe generation of HLOs from iPS cells but do not mention authentication or mycoplasma testing.”

direct quote[Methods, RNA-sequencing analysis and Statistical analyses]

“FastQC (version 0.11.9)... STAR (version 2.73a)... Limma R package (version 3.60.0)... Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

Tests are named (e.g., two-tailed Mann-Whitney U, BH adjustment, two-way ANOVA with Sidak's test). Exact p-values are reported in Table 1 and figures. Effect sizes (placebo-adjusted median percentage change) and 95% CIs are reported. Software is partially identified (e.g., R packages, Pheonix WinNonlin 6.2.1). Data presentation includes dot plots and box plots with individual points in many figures. Assumptions verification (normality, equal variance) is not mentioned; the use of non-parametric tests suggests awareness but is not explicitly justified. Mathematical plausibility: cell counts for subgroups in clinical trial (e.g., elevated TG: n=4 placebo, 3 (0.5 mg), 3 (2 mg), 8 (6 mg), 3 (12 mg)) sum to 21, but total MAD cohort is 50; likely some participants not in subgroups. No clear impossibility found. This is a 'warn' due to missing assumptions verification and partial software reporting.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedNOT REPORTED

mathematical plausibilityWARN

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Statistical tests are named for most analyses, exact p-values are often reported with effect sizes (e.g., placebo-adjusted percentage change with 95% CI), but assumptions verification and software identification are incomplete, and mathematical plausibility is not fully verified.

Evidence

direct quote[Figure legends]

“Data were analyzed by two-tailed Mann–Whitney U-test and BH adjustment”

direct quote[Table 1]

“P value versus placebo b — 0.281, 0.681, 0.003, 0.024”

direct quote[Table 1, Figure legends]

“Placebo-adjusted percentage change from day 1 to day 14 — ... −37.6 (−54.0, −19.9)”

direct quote[Methods, Statistical analyses (clinical)]

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

absence[Methods, Statistical analyses]

Assumptions verification not reported.

WARNReviewer 2· 85% conf

Statistical tests are named and software is identified, but exact p-values are often reported as ranges or adjusted values, effect sizes with confidence intervals are reported for the clinical trial, and data presentation is adequate. Assumptions verification is not reported.

Evidence

direct quote[Methods, Phase 1 clinical trial, Statistical analyses]

“For analyses of changes from baseline, two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U-tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

direct quote[Table 1]

“P value versus placebo b — 0.003”

direct quote[Results, TLC-2716 was well tolerated...]

“Placebo-adjusted median percentage changes in TG from day 1 to day 14 were −37.6% (95% confidence interval (95% CI), −54.0 to −19.9) with 6 mg and −38.5% (95% CI, −67.9 to −7.2) with 12 mg.”

WARNReviewer 3· 80% conf

Statistical tests are named; software is identified; but exact p-values and effect sizes are not consistently reported for preclinical data, assumptions are not verified, and individual data points are not shown.

Evidence

direct quote[Methods, Statistical analyses and Figure legends]

“Data were analyzed by two-tailed Mann–Whitney U -test and BH adjustment ( c – f and j – l ), two-tailed Mann–Whitney U -test ( g and h ) or two-way analysis of variance with Sidak’s multiple comparisons test ( i ).”

direct quote[Table 1 and Figure 5 legends]

“Placebo-adjusted percentage changes in TG from day 1 to day 14 were −37.6% (95% CI, −54.0 to −19.9) with 6 mg and −38.5% (95% CI, −67.9 to −7.2) with 12 mg (Fig. and Table ).”

direct quote[Figure 2 legend]

“Box plots indicate the median (center line), IQR (box bounds, 25th and 75th percentiles), and smallest and largest values within 1.5× IQR (whiskers)”

Data availability statement: exists and describes conditions for clinical data, but is 'reported_but_inadequate' (vague, no platform). Sequencing data (HLO RNA-seq) have GEO accession GSE299888. Preclinical data are 'available in the Source Data' (supplementary, not a persistent repository). Code sharing: 'This study did not generate original code' – this is acceptable (n/a). The clinical trial data statement includes a managed-access procedure (request conditions), but no platform is named. With two of three applicable criteria (data_availability_statement inadequate, repository_deposit partial, accession_numbers adequate), the pass threshold is not met.

Sub-criteria

code sharingN/A

accession numbersADEQUATE

repository depositINADEQUATE

data availability statementINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement is present, but it is vague for clinical data ('available upon reasonable request' with conditions) and the code availability statement states no original code was generated. Sequencing data have an accession number.

Evidence

direct quote[Data availability]

“The individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research aligned with the original scope of the trial.”

direct quote[Data availability]

“The HLO RNA-sequencing data are available under GEO number GSE299888.”

direct quote[Code availability]

“This study did not generate original code.”

WARNReviewer 2· 90% conf

A data availability statement is present, and HLO RNA-seq data are deposited in GEO with an accession number, but the clinical trial data are only available upon request with a vague mechanism, and no code was generated.

Evidence

direct quote[Data availability]

“The raw data for preclinical experiments and the summary results for the clinical trial phase 1 data are available in the Source Data, whereas the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions...”

direct quote[Data availability]

“The HLO RNA-sequencing data are available under GEO number GSE299888 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299888).”

direct quote[Code availability]

“This study did not generate original code.”

WARNReviewer 3· 90% conf

A data availability statement is present with a mechanism for clinical data access, but preclinical data are only available as source data in supplementary material, not in a dedicated repository.

Evidence

direct quote[Data availability section]

“The raw data for preclinical experiments and the summary results for the clinical trial phase 1 data are available in the Source Data, whereas the individual data from the phase 1 clinical trial are available upon reasonable request... The HLO RNA-sequencing data are available under GEO number GSE299888.”

direct quote[Data availability section]

“The HLO RNA-sequencing data are available under GEO number GSE299888 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299888).”

direct quote[Code availability section]

“This study did not generate original code.”

Methods: very detailed (multiple animal models, HLOs, clinical protocol). Trial registration: clinicaltrials.gov NCT05483998, adequate. Reporting guideline: the paper mentions 'Reporting Summary' and 'CONSORT checklist' in supplementary, but this is not explicitly stated to be submitted or followed; it is vague. All outcomes: not clearly pre-specified; the secondary endpoints are listed but post-hoc analyses are noted (exploratory). Limitations discussed: acceptable (e.g., small sample size, exploratory nature). Conclusions: partially proportional – the phase 1 is small and healthy participants, yet the abstract says 'well tolerated' which is reasonable, but the claim 'highlighting its potential for managing cardiovascular risk' is slightly overreaching for a phase 1 (overstated). Funding/COI: declared. This yields a 'warn' due to inadequate reporting guideline, all outcomes not clearly pre-specified, and mildly overstated conclusions.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 90% conf

Methods are detailed, trial is registered, and limitations are discussed, but the lack of a reporting guideline checklist (CONSORT for the clinical trial) and potential overclaiming in the conclusion (e.g., 'well tolerated' based on a small phase 1) lead to a 'warn'.

Evidence

direct quote[Abstract, Methods]

“ClinicalTrials.gov identifier: NCT05483998”

direct quote[Methods, Reporting summary]

“Further information on research design is available in the linked to this article.”

direct quote[Abstract, Discussion]

“highlighting its potential for managing cardiovascular risk”

direct quote[Discussion]

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

WARNReviewer 2· 85% conf

Methods are detailed, the trial is registered, and limitations are discussed, but no reporting guideline is referenced, and the conclusions are generally proportional but slightly overstate the clinical implications given the phase 1 nature.

Evidence

direct quote[Abstract]

“ClinicalTrials.gov identifier: NCT05483998 (http://clinicaltrials.gov/ct2/show/NCT05483998).”

absence[Methods]

No reporting guideline (e.g., CONSORT) is mentioned in the methods.

direct quote[Abstract]

“In conclusion, these results highlight the tolerability and therapeutic potential of TLC-2716 as a treatment for managing dyslipidemia and reducing residual atherosclerotic cardiovascular disease risk in humans.”

PASSReviewer 3· 95% conf

The trial is registered, a CONSORT checklist is referenced, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. Methods could be more detailed but are generally adequate.

Evidence

direct quote[Abstract and Methods]

“ClinicalTrials.gov identifier: NCT05483998 (http://clinicaltrials.gov/ct2/show/NCT05483998).”

direct quote[Discussion, paragraph 6]

“Given the small sample size of each group, sex is not considered in the analysis.”

direct quote[Competing interests section]

“A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio, and J.A. and T.T. are advisors to OrsoBio. C.K. is employed by WM Therapeutics. The other authors declare no competing interests.”

8 copyedit issues flagged: mostly consistency, clarity, grammar.

Checked 72 references: 1 verified — 71 not checked.

Reproducibility

8 data/code links checked; 7 live.

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Adcurare Rigor Action ItemsFinal pass before journal submission

The manuscript is not ready for submission in its current form. It requires substantive revision to address the identified rigor gaps — particularly the missing randomization/blinding, animal biological variable reporting, and key resource identification — before it meets the standards of a high-quality journal. The copyedit issues are minor and can be addressed concurrently.

1.
HIGHrigor
Report the randomization method (e.g., computer-generated random sequence) and whether allocation was concealed for the phase 1 trial in the Methods, Study design section.
Without this, the study cannot be evaluated for internal validity and risks rejection.
2.
HIGHrigor
Add a statement on blinding for all preclinical experiments (who was blinded during outcome assessment, allocation concealment) and for the phase 1 trial (e.g., double-blind, open-label) in the Methods.
Blinding is a fundamental bias-control measure; its absence undermines credibility.
3.
HIGHreporting
Report sex, age, and weight for every animal experiment (DIO mice, SD rats, ZDF rats) in the Results or figure legends, and provide a scientific justification if only one sex was used.
Missing biological variables prevent reproducibility and generalization.
4.
HIGHrigor
Provide authentication certificates (e.g., STR profiling) for the iPS cell lines used in organoid studies and state mycoplasma testing results in the Methods, HLO models section.
Unvalidated cell lines are a known source of irreproducibility.
5.
HIGHdata code
Deposit all preclinical raw data in a public repository (e.g., Dryad, Figshare) with a persistent DOI, not only as supplementary source data.
Supplementary material is not a permanent, citable repository and does not meet modern data-sharing standards.
6.
HIGHrigor
Add a formal power analysis or at minimum a sample size rationale for the phase 1 primary endpoint, even if exploratory, in the Methods, Statistical analyses section.
Reviewers and editors expect sample size justification; the current statement is insufficient.
7.
HIGHreporting
Explicitly state that a CONSORT checklist was completed and submitted, and reference it by name (e.g., 'The CONSORT checklist is provided in the Supplementary Information') in the Methods, Reporting summary section.
Transparent reporting guidelines are standard for clinical trials.
8.
HIGHreporting
Tone down the conclusion that TLC-2716 'has potential for managing cardiovascular risk' to reflect exploratory phase 1 data in healthy participants; rephrase to 'suggesting potential for further investigation' in the Abstract and Discussion.
Overstated conclusions are the most common reviewer objection and can mislead readers.
9.
HIGHethics
Name the specific institution that approved the animal studies and include a protocol number in the Methods, Toxicity study section.
A generic 'IACUC' without institution or protocol number is inadequate for verification.
10.
MEDIUMrigor
Add catalog numbers or RRIDs for all key reagents (e.g., BODIPY 493/503, sodium oleate, cell culture components) in the Methods.
Enables exact replication of experiments.
11.
MEDIUMstatistics
Report exact p-values (e.g., 'P = 0.003') consistently for all comparisons, including preclinical, rather than thresholds alone, in figure legends and tables.
Threshold p-values ('P < 0.05') are less informative and are not best practice.
12.
MEDIUMstatistics
Show individual data points (scatter overlay) in all box/bar plots to improve transparency in figures.
Box plots alone can hide the data distribution and sample size.
13.
MEDIUMstatistics
Add a statement describing how assumptions (e.g., normality, equal variance) were verified or why non-parametric tests were chosen in the Methods, Statistical analyses section.
Provides confidence that the chosen tests are appropriate.
14.
MEDIUMdata code
Provide a managed-access platform (e.g., Vivli, YODA) for clinical data requests rather than 'upon reasonable request' in the Data availability statement.
Managed-access platforms provide a transparent and consistent process.
15.
MEDIUMreporting
Report the race/ethnicity of human participants in the phase 1 trial baseline demographics (Table 1 or text).
Demographic reporting is a standard CONSORT recommendation.
16.
LOWcopyedit
Clarify if the VLDL cholesterol row in Table 1 is a duplicate of the RC (predose) row or a different metric; correct if erroneous.
Identical values for different biomarkers appear to be a copy-paste error.
17.
LOWcopyedit
Rephrase 'gut- and liver-restricted' to 'restricted to the liver and gut' for clarity in the Abstract.
Stylistic improvement.
18.
LOWcopyedit
Break the dense Figure 2 legend into separate panel descriptions for clarity.
Improves readability.
19.
LOWethics
Add a statement that the clinical trial was conducted in accordance with the Declaration of Helsinki or ICH-GCP, rather than 'relevant local regulatory policies', in the Methods, Study oversight section.
Aligns with standard ethical reporting.

Full text (86,299 chars · analyzed ~87%, head + tail)Analyzed: Jul 7, 2026

Read alongside